Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment.

Abstract

BACKGROUND\nClinical trials with putative antidepressants can be difficult to execute as it can take up to 8\u2009weeks before differences emerge between drug and placebo, and long expensive trials often fail. Implementation of early response biomarkers could aid this process significantly with potential to identify new treatments.\n\n\nAIMS\nIn a secondary analysis, we examined the association of early effects on emotional processing with later clinical outcome following treatment with the novel NOP antagonist LY2940094 versus placebo. We hypothesised that early induction of positive bias would be associated with reduced severity of depression after 8\u2009weeks of treatment.\n\n\nMETHODS\nThis was a multicentre, randomised, double-blind, parallel-group, fixed-dose, placebo-controlled, 8\u2009week study to assess sensitivity of the facial emotional recognition task (FERT) to early changes in emotional bias induced by LY2940094. Patients who met diagnostic criteria for major depression were randomised to receive LY2940094 (N\u2009=\u200970) or placebo (N\u2009=\u200966). At week 1 and 6, the FERT was completed by 33 patients in the LY2940094 group and 34 in the placebo group.\n\n\nRESULTS\nPatients identified happy faces with higher accuracy (Wald χ2(1,33)\u2009=\u200914.25, p\u2009<\u20090.001) after 1\u2009week treatment with LY290094 compared to placebo (Wald χ2(1,32)\u2009=\u20090.83, p\u2009=\u20090.36) and this correlated with eventual treatment response measured by the Hamilton Depression Rating Scale 7\u2009weeks later.\n\n\nCONCLUSION\nThese data suggest that emotional processing biomarkers may be sensitive to early effects of antidepressant treatment indicative of later clinical response. Further studies in this area may be useful in developing new treatments and clinical trial designs for predicting antidepressant response.